AIRS

AirSculpt Technologies, Inc.

Beauty '26: Medical Aesthetics GLP-1 Long '24: Improved Looks MedTech Long '25: Elective Aesthetics

Loading…

Overview

AirSculpt Technologies runs branded clinics called Elite Body Sculpture that perform a modern, minimally invasive version of liposuction using its AirSculpt® te

AirSculpt Technologies runs branded clinics called Elite Body Sculpture that perform a modern, minimally invasive version of liposuction using its AirSculpt® technique. It removes fat precisely through small openings under local anesthesia and also offers skin tightening, cellulite smoothing, and fat transfer (e.g., breast or buttock shaping). The company reports one revenue segment — direct medical procedure services (100%). It sells directly to individual, cash-pay consumers; no single customer dominates sales.

Bull / Bear Details

AirSculpt (AIRS) is stabilizing after a difficult year, with record leads, improved marketing efficiency, and a delevered balance sheet positioning it for a pot

Thesis

AirSculpt (AIRS) is stabilizing after a difficult year, with record leads, improved marketing efficiency, and a delevered balance sheet positioning it for a potential recovery in 2026. The next quarter hinges on converting leads into booked cases and proving new GLP-1-linked procedures (skin tightening) can expand its market.

Bull case

Lead funnel and consultations at record highs indicate underlying demand remains strong despite macro softness.
Cost controls and lower CAC are improving margins and cash flow, supporting guidance even with flat revenue.
GLP-1–adjacent treatments (skin tightening) could open a new, high-margin service line and refresh the brand narrative.

Bear case

Same-store sales still down >20% YoY, showing weak conversion and limited near-term revenue visibility.
Consumer spending on elective procedures remains fragile and financing dependence is rising.
New offerings and digital initiatives are early-stage with limited proof they can offset case volume declines.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Peer results from elective-aesthetic companies (InMode, Cutera, AbbVie/CoolSculpting)	Provides read-through on industry demand and consumer confidence.	Revenue growth and case volumes in peer earnings.	Peers show flat or positive QoQ growth = bullish setup for AIRS; peers show >10% declines = bearish.	Earnings calendar (Nov 2025 for peers)	Yahoo Finance or Seeking Alpha transcripts	FactSet or Visible Alpha peer comps
Same-store sales update (from mgmt channel checks or peer read-through)	Key indicator of core health; a narrowing decline signals stabilization.	Sequential or YoY same-store revenue change.	Decline narrows to <–10% YoY = bullish; remains >–20% = bearish.	Q3 earnings (expected early Feb 2026)	Glassdoor hiring trends at Elite Body Sculpture clinics	Placer.ai foot-traffic data to clinics
Monthly Google search trends for “AirSculpt,” “Elite Body Sculpture,” and “skin tightening after GLP-1”	Measures brand interest and early funnel activity, which historically leads actual procedure volume by ~1–2 months.	MoM and YoY change in search volume.	>+10% MoM = bullish (lead growth sustaining); <–10% = bearish (interest fading).	Google Trends (track weekly)	Google Trends, Reddit (r/PlasticSurgery, r/Ozempic)	Similarweb or Yipit clickstream on AirSculpt/EliteBody sites
Expansion or update on skin-tightening pilot	Ties directly to GLP-1 tailwinds and expanding TAM.	# of clinics offering the pilot; commentary on attach rates.	Expanded to >8 clinics or included in guidance = bullish; no update or scaling back = bearish.	Company press releases / IR site	Social mentions (“AirSculpt skin tightening,” “AirSculpt Smooth”)	M Science aesthetic treatment volume tracker; credit-card panel data by procedure
Credit-card or financing utilization rates	High financing uptake shows demand elasticity; drop-off could indicate affordability strain or fading interest.	% of procedures financed vs. Q2 baseline (50%).	>55% financedwith stable ARPC = bullish; <45% = bearish (financing availability or demand issue).	Next 10-Q (Feb 2026) / management commentary	Reddit threads on financing approvals; Google search “CareCredit AirSculpt” trends	Facteus consumer spend data; Earnest or Yipit financing trackers

Key Reported Metrics3 rows

Metric	Why It Matters	Last Period
Case Volume (Procedures Performed)	Direct signal of consumer conversion and utilization across centers; leads to revenue inflection and margin leverage.	–14.1% YoY (3,392 cases in Q2 FY25)
Same-Store Revenue Growth	Key indicator of underlying health of mature clinics; management's top focus before any new openings.	–22% YoY (Q2 FY25)
Total Revenue	Core measure of demand and pricing; reflects whether record leads and new financing options are converting to booked procedures.	–13.7% YoY (Q2 FY25: $44.0M vs. $51.0M)

Key Questions

Can AirSculpt convert record lead and consultation volume into higher case counts and stabilize same-store revenue declines?

Question 2: Will the new skin-tightening pilot tied to GLP-1 users show measurable traction or remain too small to impact results?
Question 3: Can margins and cash flow continue improving despite flat revenue, validating management's cost-control strategy during a weak macro backdrop?

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	IS CHANGE	Price Reaction
2025-08-01	Q2 showed stabilizing trends: revenue $44M (-13.7% YoY) with record leads, steady ARPC, and improving EBITDA margin (13.3%). Management reiterated FY25 guidance ($160–170M rev, $16–18M EBITDA) as marketing efficiency, financing expansion, and a GLP-1-linked skin-tightening pilot gain traction. Consumer hesitancy and 22% same-store decline weighed on sentiment, yielding a muted (~3%) stock reaction.	Earnings Transcript	Mixed			-10.51% (vs SPY: -10.37%)